De-escalating Surgery Among Patients with HER2+and Triple Negative Breast Cancer

被引：2
|
作者：
Tasoulis, Marios-Konstantinos [1 ,2 ]
Heil, Joerg [3 ]
Kuerer, Henry M. [4 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Breast Surg Unit, Fulham Rd, London SW3 6JJ, England
[2] Inst Canc Res, Div Breast Canc Res, Old Brompton Rd, London SW7 3RP, England
[3] Heidelberg Univ Hosp, Univ Breast Unit, Dept Obstet & Gynecol, Heidelberg, Germany
[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
来源：
CURRENT BREAST CANCER REPORTS | 2022年 / 14卷 / 04期
关键词：
Surgical de-escalation; Breast surgery; Triple negative; HER2; positive; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; SENTINEL NODE BIOPSY; 20-YEAR FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY; RADICAL-MASTECTOMY; MULTICENTER; TRIAL; IDENTIFICATION; AXILLA; IMPACT;
D O I：
10.1007/s12609-022-00453-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of Review De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions. Recent Findings Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery. Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders.
引用
收藏
页码：135 / 141
页数：7
相关论文
共 50 条
  • [31] ASO Author Reflections: De-escalating Axillary Surgery in Patients with Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy
    So, Alycia
    Hunt, Kelly K.
    ANNALS OF SURGICAL ONCOLOGY, 2024,
  • [32] Prognostic impact of immune interactions in HER2+and triple-negative breast cancer brain metastases
    Griguolo, G.
    Tosi, A.
    Dieci, M. V.
    Fineberg, S.
    Ventura, A.
    Bottosso, M.
    Bauchet, L.
    Miglietta, F.
    Jacob, J.
    Rossi, V.
    Rigau, V.
    Jacot, W.
    Conte, P. F.
    Rosato, A.
    Darlix, A.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S486 - S487
  • [33] De-escalating axillary surgery according to neoadjuvant single or dual HER2 blockade in clinically node-positive, HER2-positive breast cancer
    Cha, C.
    Kim, D.
    Lee, J.
    Park, S.
    Bae, S. J.
    Kim, J. Y.
    Ahn, S. G.
    Park, H. S.
    Park, S.
    Kim, S. I.
    Cho, Y. U.
    Jeong, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Clinical Significance of HER2+and Triple-Negative Status in Patients with Tumor Size ≤ 1 cm and Node Negative Breast Cancer.
    Shao, T.
    Boolbol, S. K.
    Boachie-Adjei, K.
    Klein, P.
    CANCER RESEARCH, 2011, 71
  • [35] Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
    Dharanikota, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1482 - S1482
  • [36] Tumor infiltrating lymphocytes in recurrent HER2+and triple negative breast cancer: Prognostic value according to tumor phenotype
    Dieci, M. V.
    Giaratano, T.
    Miglietta, F.
    Griguolo, G.
    Orvieto, E.
    Falci, C.
    Giorgi, C. A.
    Mioranza, E.
    Tasca, G.
    Cappellesso, R.
    Ghiotto, C.
    Conte, P.
    Guarneri, V.
    CANCER RESEARCH, 2017, 77
  • [37] De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy
    de Wild, Sabine R.
    Simons, Janine M.
    Vrancken Peeters, Marie-Jeanne T. F. D.
    Smidt, Marjolein L.
    Koppert, Linetta B.
    BREAST CARE, 2021, 16 (06) : 584 - 589
  • [38] Development of rational combination therapy strategies to optimize treatment for GPNMB expressing Her2+and triple negative breast cancer
    Rose, A.
    Maric, G.
    Annis, M. G.
    Smith, H.
    Muller, W. J.
    Siegel, P. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 22 - 22
  • [39] Differences in axillary ultrasound protocols among prospective de-escalating axillary surgical staging trials in clinically node negative early breast cancer patients
    van Nijnatten, T. J. A.
    Poplack, S. P.
    Wijgers, R. A.
    Kilburn-Toppin, F.
    Athanasiou, A.
    Chang, J. M.
    Smidt, M. L.
    EUROPEAN JOURNAL OF RADIOLOGY, 2024, 181
  • [40] Clinical features and course of brain metastases in triple-negative breast cancer: Comparison with HER2+and other type
    Jang, G.
    Lee, S.
    Ahn, J.
    Jung, K.
    Lee, H.
    Gong, G.
    Kim, H.
    Ahn, S.
    Ahn, S.
    Kim, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345